Wave Life Sciences

WAVE Life Sciences is a preclinical genetic medicine company focused on advancing first-in-class or best-in-class stereopure nucleic acid therapies for patients impacted by rare diseases. We are utilizing our innovative and proprietary synthetic chemistry platform to design and develop nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, with a goal of delivering new and exceptional treatment options for patients. Given the versatility of our chemistry, WAVE’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi, potentially enabling us to address a broad range of therapeutic areas and diseases.

Type
Public
HQ
Cambridge, US
Founded
2012
Employees
41 (est)
Wave Life Sciences was founded in 2012 and is headquartered in Cambridge, US

Wave Life Sciences Locations

Cambridge, US

Wave Life Sciences Metrics

Wave Life Sciences Summary

Market capitalization

$805 M

Closing share price

$37
Wave Life Sciences's latest market capitalization is $805 M.

Wave Life Sciences Market Value History

Wave Life Sciences News

Wave Life Sciences Company Life

You may also be interested in